Candel Therapeutics, Inc. (CADL): who owns it and who trades it
As of Nov 16, 2026, CADL insiders reported 5 open-market sales worth $3.6M and 1 purchase worth $3M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Paul Peter Tak (CEO), with $3.2M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Candel Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns CADL
138 funds and institutions reported CADL shares worth $521M at the end of Q2 2026, about 69% of the company. The largest holder is FMR LLC (Fidelity) with 15.0%.
Funds and institutions (13F) 69%Everyone else 31%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 10.99M | 15.00% | $113M | No change |
| Rtw Investments, LP | 6.42M | 8.77% | $66.1M | No change |
| BlackRock, Inc. | 4.97M | 6.78% | $51.2M | +60% |
| State Street Corp | 3.55M | 4.85% | $36.6M | +334% |
| Acorn Capital Advisors, LLC | 3.50M | 4.78% | $36M | No change |
| Portolan Capital Management, LLC | 3.49M | 4.77% | $36M | +21% |
| Saturn V Capital Management LP | 3.30M | 4.51% | $34M | +14% |
| Vanguard Capital Management LLC | 2.69M | 3.68% | $27.7M | +9% |
| Geode Capital Management, LLC | 1.57M | 2.14% | $16.2M | +52% |
| Millennium Management LLC | 1.09M | 1.49% | $11.3M | +3% |
| Halter Ferguson Financial Inc. | 772,461 | 1.05% | $8M | -15% |
| Northern Trust Corp | 492,465 | 0.67% | $5.1M | +52% |
| Kennedy Capital Management LLC | 488,291 | 0.67% | $5M | +427% |
| Vanguard Portfolio Management LLC | 437,150 | 0.60% | $4.5M | +63% |
| Vanguard Fiduciary Trust Co | 412,109 | 0.56% | $4.2M | +47% |
| Sands Capital Alternatives, LLC | 405,837 | 0.55% | $4.2M | No change |
| Goldman Sachs Group Inc | 305,216 | 0.42% | $3.1M | +34% |
| Marshall Wace, LLP | 300,641 | 0.41% | $3.1M | – |
| Bank of America Corp | 278,944 | 0.38% | $2.9M | +488% |
| Susquehanna International Group, LLP | 227,939 | 0.31% | $2.3M | +102% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, CADL insiders reported $3M of open-market purchases and $3.6M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Paul Peter Tak | CEO | Sale | 59,379 | $10.46 | $621K | Form 4 |
| Sep 10, 2026 | Paul Peter Tak | CEO | Sale | 220,866 | $11.50 | $2.5M | Form 4 |
| Aug 17, 2026 | Seshu Tyagarajan | Chief Technology Officer | Sale | 7,000 | $12.00 | $84K | Form 4 |
| Jun 29, 2026 | Francesca Barone | Chief Scientific Officer | Sale | 23,447 | $10.06 | $236K | Form 4 |
| Jun 29, 2026 | Seshu Tyagarajan | Chief Technology Officer | Sale | 7,000 | $10.02 | $70.1K | Form 4 |
| Feb 23, 2026 | Paul B Manning | Director | Purchase | 550,458 | $5.45 | $3M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Paul Peter Tak | Chief Executive Officer, Director | – | $3.2M | Sep 11, 2026 |
| Paul B Manning | Director | $3M | – | Feb 23, 2026 |
| Francesca Barone | Chief Scientific Officer | – | $236K | Jun 29, 2026 |
| Seshu Tyagarajan | Chief Technology Officer | – | $154K | Aug 17, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CADL short interest
High short interest. 17.1% of CADL shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went down 9%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 13.09M CADL shares were sold short, 17.1% of the shares outstanding, up 2.5% from the report before. At the average daily volume of 983,284 shares, buying them all back would take about 13.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 13.09M | 17.10% | +2% | 983,284 | 13.3 |
| Oct 15, 2026 | 12.77M | 16.69% | -2% | 907,006 | 14.1 |
| Sep 30, 2026 | 13.00M | 16.99% | +5% | 1.17M | 11.2 |
| Sep 15, 2026 | 12.34M | 16.13% | +1% | 1.20M | 10.3 |
| Aug 31, 2026 | 12.27M | 16.03% | -2% | 1.33M | 9.2 |
| Aug 14, 2026 | 12.46M | 16.29% | -2% | 1.18M | 10.6 |
| Jul 31, 2026 | 12.66M | 17.28% | -2% | 1.22M | 10.4 |
| Jul 15, 2026 | 12.96M | 17.70% | -20% | 1.44M | 9.0 |
| Jun 30, 2026 | 16.14M | 22.03% | +18% | 2.70M | 6.0 |
| Jun 15, 2026 | 13.62M | 18.59% | -4% | 1.80M | 7.6 |
| May 29, 2026 | 14.16M | 19.34% | -2% | 1.85M | 7.6 |
| May 15, 2026 | 14.42M | 19.69% | -2% | 2.60M | 5.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Candel Therapeutics company events
Candel Therapeutics filed 11 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Sep 10, 2026.
- Sep 10, 2026LeadershipThe Board of Directors of Candel Therapeutics, Inc. increased the size of the Board from ten (10) to eleven (11) directors and unanimously appointed Martine Zimmermann, Pharm.D, to fill the newly created vacancy on the Board, effective September 8, 2026. Filing
- Sep 9, 2026AnnouncementShared information with investors. Filing
- Aug 13, 2026ResultsReleased financial results. Filing
- Jun 24, 2026VoteReported shareholder vote results. Filing
- Jun 16, 2026LeadershipCandel Therapeutics, Inc. entered into an employment agreement with Charles Schoch, the Company’s Chief Financial Officer. Filing
- May 15, 2026AnnouncementShared information with investors. Filing
- May 14, 2026ResultsReleased financial results. Filing
- Mar 12, 2026ResultsReleased financial results. Filing
- Feb 23, 2026AgreementCandel Therapeutics, Inc. entered into an underwriting agreement with Citigroup Global Markets Inc., Cantor Fitzgerald & Co., and Stifel, Nicolaus & Company, Incorporated, as representatives of the underwriters named therein, pursuant to which the Company agreed to issue and sell an aggregate of… Filing
- Feb 19, 2026AgreementCandel Therapeutics, Inc. announced its entry into a purchase and sale agreement with funds managed by RTW Investments, LP. Filing
- Dec 5, 2025AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Candel Therapeutics financials
Famous investors that hold CADL
5 of the 50 well-known investors we track reported holding CADL in their latest 13F filing. The largest position is Israel Englander's, worth $10.1M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 971,394 | $10.1M | 0.0% | -11% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 373,710 | $3.9M | 0.0% | +156% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 335,108 | $3.5M | 0.0% | +159% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 57,800 | $603K | 0.0% | No change |
| Jim Simons · Renaissance Technologies | Q3 2026 | 26,812 | $280K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named CADL in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | RTW Investments, LP | 13G/A | 4.2% |
| Nov 16, 2026 | RTW Investments, LP | 13G/A | 4.2% |
Questions about Candel Therapeutics, Inc. (CADL) stock
Who owns the most CADL stock?
The largest reported owner of Candel Therapeutics, Inc. (CADL) is FMR LLC (Fidelity), with 15.0% of the company. In total, 138 funds and institutions reported holding CADL at the end of Q2 2026, together about 69% of the shares. See the largest owners.
Are CADL insiders buying or selling?
In the last 12 months, CADL insiders reported 1 open-market purchase worth $3M and 5 sales worth $3.6M. The latest trade was on Sep 11, 2026. See every trade.
What is the short interest in CADL?
As of Oct 30, 2026, 13.09M CADL shares were sold short, 17.1% of the shares outstanding, up 2.5% from the report before. At the average daily volume of 983,284 shares, buying them all back would take about 13.3 trading days (days to cover). See the history.
Which famous investors hold CADL?
5 of the 50 well-known investors we track reported CADL in their latest 13F filing, including Israel Englander, Ken Griffin, Steve Cohen. The largest position is worth $10.1M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.